FDA Commissioner Marty Makary's Position in Doubt Amid Reports of White House Discord
Trump appeared to have spared Makary after reports authorized his firing, though Trump has approved a plan to fire Makary with timing remaining unknown and the president able to change his mind.
Objective Facts
White House officials signed off on a plan to replace FDA Commissioner Marty Makary after months of turmoil at the agency and criticism of his decisions. President Trump reportedly signed off on a plan to dismiss Makary, though the timing remains unknown and the president could change his mind. The discord centers on multiple policy areas: Trump wanted Makary to approve flavored vapes to appease young MAGA voters but Makary tried to block agency scientists from approving them, and Makary angered anti-abortion groups by slow-walking a safety study on the abortion pill mifepristone. The agency has been mired in high-profile departures, feuds between top leaders, accusations of politicization and low morale. Kyle Diamantas, FDA Deputy Commissioner overseeing the food division, is among candidates under consideration to act as commissioner if Makary exits.
Left-Leaning Perspective
Progressive outlets like STAT News and PBS News Hour reported extensively on the turmoil at the FDA under Makary, with STAT reporter Lizzy Lawrence documenting the personnel drama and controversy over political pressure on FDA decisions. PBS's Stephanie Sy interviewed Wall Street Journal health reporter Liz Whyte, who noted Makary struggled with balancing politics and his regulatory role, particularly over misfeasance on abortion pill reviews and vape approvals. Their reporting characterized the FDA as dysfunctional under his leadership, with departing staff and internal chaos preventing the agency from executing its mission. Progressive coverage emphasized systemic damage from political interference rather than celebrating Makary's removal. STAT highlighted concerns that another leadership change would compound existing gaps in expertise, with both FDA drug divisions already headed by acting directors. Outlets focused on institutional continuity concerns during an election year when agencies already lack permanent CDC and surgeon general leadership. The coverage implied that Makary was a symptom of broader White House instability in health agencies rather than the root cause. Progressive outlets largely avoided defending Makary's specific policy decisions while emphasizing that his ouster would worsen FDA capacity. They downplayed the possibility that removing him would meaningfully improve agency performance without addressing underlying White House politicization of the regulatory process.
Right-Leaning Perspective
Conservative outlets including the Wall Street Journal editorial board, Washington Examiner, and outlets aligned with the Trump administration mounted a sustained critique of Makary. Former Senator Rick Santorum, who initially supported his nomination, wrote on social media that Makary had fired experienced FDA leaders and replaced them with "anti-Trump leftists," accusations echoing broader conservative complaints about his management. The Wall Street Journal published more than a dozen editorial pieces criticizing Makary's stewardship, particularly his handling of rare-disease drug approvals and his resistance to fast-tracking vape products Trump had pledged to protect. Right-leaning voices viewed Makary's potential removal as necessary accountability for failing to execute the administration's regulatory agenda. Anti-abortion groups led by Susan B. Anthony Pro-Life America President Marjorie Dannenfelser called for his immediate firing over delays on mifepristone safety reviews. Biotech industry groups also weighed in, with John Crowley of the Biotechnology Innovation Organization criticizing his personnel cuts. This created unusual alignment across Trump allies, industry, and social conservatives demanding his ouster. Right-leaning outlets framed the discord as evidence that Makary had failed to deliver promised FDA reform. They argued his resistance to vape approvals and alleged foot-dragging on abortion pill restrictions showed he lacked commitment to the administration's priorities, not that those priorities themselves were problematic.
Deep Dive
Makary's position deteriorated under cross-cutting pressure from multiple Trump-aligned constituencies simultaneously. The White House faced demands from anti-abortion groups who wanted aggressive action on mifepristone restrictions, pharmaceutical and biotech companies frustrated by drug approval slowdowns, and Trump himself angry over vape policy. This multi-directional fire was unusual: conservatives typically disagree on regulatory scope, but Makary somehow disappointed all of them at once. The vape issue became the immediate breaking point after Trump publicly expressed frustration, but it masked deeper institutional failures—high turnover, departing experienced staff, and internal feuds that made the agency feel chaotic to both the White House and regulated industries. Makary's core problem was managerial, not ideological. He entered the FDA with strong conservative credentials as a COVID skeptic and MAHA ally, but running a 16,000-person agency proved vastly different from writing op-eds or appearing on cable news. HHS Secretary Kennedy had even considered making him a figurehead and installing someone else to handle day-to-day operations in 2025. By May 2026, his loss of control over the agency itself—not disagreement with Trump's policies—became the actual issue. The FDA faced accusations of both moving too slowly on industry priorities and moving too fast on controversial issues, suggesting the problem was inconsistent direction from leadership rather than principled obstruction. What happens next will test whether the issue was Makary's personal failure or structural. If a successor like Kyle Diamantas or returning figures like Stephen Hahn can restore predictability and staff confidence while delivering on Trump's regulatory agenda, it suggests Makary was the limiting factor. If instability persists and the FDA continues to swing between competing demands from anti-abortion groups, industry, and the White House, it suggests the problem is the impossible position of running a major regulatory agency under constant politicization.